Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12‐week, double‐blind, randomized, placebo‐controlled, multicentre trial

Pattzi, H.M. Rodriquez; Pitale, Shailesh; Alpizar, Melchor; Bennett, Cavan; O'Farrell, A. Marie; Li, J.; Cherrington, Julie M.; Guler, Hans‐Peter

doi:10.1111/j.1463-1326.2010.01195.x

Cited by 35 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in PG AUC are used to evaluate the efficacy of medicines such as a-glucosidase inhibitors or nateglinide for postprandial hyperglycemia 18,19 . This trend is also apparent in the evaluation of recently developed medicines, such as incretin-related agents and sodium-glucose cotransporter type 2 inhibitors, both of which act by suppressing increases in postprandial glucose levels 20,21 . Nevertheless, there are no definitive guidelines in regard to PG AUC criteria for glucose intolerance screening or diagnosis.…”

Section: Discussionmentioning

confidence: 98%

Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients

Sakamoto

Kubo

Yoshiuchi

et al. 2013

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction: To realize the effectiveness of a novel system for measuring glucose area under the curve (AUC) using minimally invasive interstitial fluid extraction technology (MIET), outpatients undergoing oral glucose tolerance tests (OGTT) were investigated for the efficacy of screening for glucose intolerance using this system. Materials and Methods: Fifty outpatients scheduled to undergo a 75-g OGTT for medical reasons were recruited to the study. An area of skin on the forearm was pretreated with microneedle arrays before the application of hydrogels for interstitial fluid extraction. Plasma glucose (PG) levels were measured every 30 min for 2 h to calculate reference (actual) AUC. The AUC was predicted by MIET on the basis of glucose extracted by the hydrogel using sodium ion levels as the internal standard. Results: Good correlation between MIET-predicted and reference AUCs obtained using PG levels was confirmed for a wide AUC range. By introducing a threshold level for AUC to separate glucose intolerance with peak glucose ‡180 mg/dL from normal glucose tolerance, the system was demonstrated to provide better screening accuracy compared with conventional methods that use HbA1c and fasting PG levels. The results of a questionnaire-based survey administered to the subjects suggested that this system was readily accepted by the majority as a painless monitoring method. Conclusions: The findings suggest that our glucose AUC measurement system using MIET would be useful for screening of glucose intolerance. In the future, this system may prove to be a useful aid as a screen for glucose intolerance before performing an OGTT for diagnosis. (J Diabetes Invest,

show abstract

Section: Discussionmentioning

confidence: 98%

Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients

Sakamoto

Kubo

Yoshiuchi

et al. 2013

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…Any change in the plasma AUC of dutogliptin or metformin within the 0.50-2.0 bound was predefined as lack of a clinically meaningful pharmacokinetic interaction based on the following. Single doses of dutogliptin of up to 3200 mg/day, eight times the highest anticipated clinical dose level, were well tolerated by 53 healthy volunteers 26 , while a lower dose of 200 mg still resulted in near complete DPP4 inhibition and showed changes of HbA 1c 12,27 . For metformin, the typically administered dose range is from 500 mg to 2550 mg/day [28][29] .…”

Section: Discussionmentioning

confidence: 96%

Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients

Li¹,

Klemm²,

O'Farrell³

et al. 2010

Current Medical Research and Opinion

View full text Add to dashboard Cite

In this small, multiple dose study, the steady state pharmacokinetics of either dutogliptin or metformin were not altered by co-administration of the two agents. Dutogliptin and metformin were well tolerated either alone or in combination and co-administered metformin did not alter the ex vivo DPP4 inhibition by dutogliptin. There is no need to consider pharmacokinetic and pharmacodynamic interactions when determining the dosage of either agent for co-administration. A phase 3 clinical trial is underway to provide more definitive data on the safety and efficacy of dutogliptin administered on a background of metformin treatment.

show abstract

“…20,21 However, there is no well-established evidence regarding glucose AUC measurements with regard to screening for glucose intolerance or for achieving optimal levels of DM management. Therefore, further investigations must be conducted to improve this system for these purposes.…”

Section: Effectiveness Of the Interstitial Fluid Glucose Area Under Tmentioning

confidence: 99%

Evaluation of a Minimally Invasive System for Measuring Glucose Area under the Curve during Oral Glucose Tolerance Tests: Usefulness of Sweat Monitoring for Precise Measurement

Sakaguchi

Hirota

Hashimoto

et al. 2013

J Diabetes Sci Technol

View full text Add to dashboard Cite

Abbreviations: (ADA) American Diabetes Association, (AUC) area under the curve, (CGM) continuous glucose monitoring, (DM) diabetes mellitus, (FPG) fasting plasma glucose, (IDF) International Diabetes Federation, (IG) interstitial fluid glucose, (IRI) immunoreactive insulin, (ISF) interstitial fluid, (MIET) minimally invasive interstitial fluid extraction technology, (OGTT) oral glucose tolerance test, (PG) plasma glucose, (SMBG) selfmonitoring of blood glucose

show abstract

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12‐week, double‐blind, randomized, placebo‐controlled, multicentre trial

Cited by 35 publications

References 24 publications

Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients

Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients

Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients

Evaluation of a Minimally Invasive System for Measuring Glucose Area under the Curve during Oral Glucose Tolerance Tests: Usefulness of Sweat Monitoring for Precise Measurement

Contact Info

Product

Resources

About